OSENI Drug Patent Profile

Which patents cover Oseni, and what generic alternatives are available?

Oseni is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Oseni

Oseni was eligible for patent challenges on January 25, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 4, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OSENI

International Patents:	101
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	2
Patent Applications:	83
Drug Prices:	Drug price information for OSENI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OSENI
What excipients (inactive ingredients) are in OSENI?	OSENI excipients list
DailyMed Link:	OSENI at DailyMed

See drug prices for OSENI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OSENI

NDA:

022426

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OSENI

Drug Class	Dipeptidyl Peptidase 4 Inhibitor Peroxisome Proliferator Receptor alpha Agonist Peroxisome Proliferator Receptor gamma Agonist Thiazolidinedione
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors Peroxisome Proliferator-activated Receptor alpha Agonists Peroxisome Proliferator-activated Receptor gamma Agonists

US Patents and Regulatory Information for OSENI

OSENI is protected by two US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-004	Jan 25, 2013		DISCN	Yes	No			Y	Y
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-001	Jan 25, 2013		RX	Yes	No			Y	Y
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-005	Jan 25, 2013		RX	Yes	No			Y

Expired US Patents for OSENI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-003	Jan 25, 2013
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-005	Jan 25, 2013
Takeda Pharms Usa	OSENI	alogliptin benzoate; pioglitazone hydrochloride	TABLET;ORAL	022426-004	Jan 25, 2013

International Patents for OSENI

When does loss-of-exclusivity occur for OSENI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Austria

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Germany

Hong Kong

Israel

Japan

Jordan

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OSENI around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	E488227
Luxembourg	92614
Japan	2017008092	グルコース代謝を調節する方法、およびそれに関連する試薬 (METHODS FOR REGULATING GLUCOSE METABOLISM AND REAGENTS RELATED THERETO)

Supplementary Protection Certificates for OSENI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1084705	C01084705/03	Switzerland		PRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 59390 05.02.2010
1586571	CR 2014 00011	Denmark		PRODUCT NAME: ALOGLIPTIN; REG. NO/DATE: EU/1/13/844/001-027 20130923
1174135	SPC/GB10/011	United Kingdom		PRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU

OSENI (alogliptin + pioglitazone) Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is OSENI’s market positioning?

OSENI is an oral, fixed-dose combination of the DPP-4 inhibitor alogliptin and the thiazolidinedione pioglitazone, prescribed for type 2 diabetes mellitus. The product is positioned as a second-line escalation option for patients needing combination therapy where monotherapy is insufficient, typically after trials of lifestyle and/or single-agent therapy.

From a market-structure perspective, OSENI competes in an intensely crowded oral diabetes class:

• DPP-4 inhibitors (alogliptin sits in a class now heavily pressured by GLP-1 receptor agonists and SGLT2 inhibitors)
• Pioglitazone-containing regimens (older, generic backbone in many markets)
• Combination fixed-dose therapy versus loose combinations and broad formularies

How has competition reshaped demand for DPP-4 plus TZD regimens?

The dominant dynamic in US and major ex-US diabetes markets is class substitution:

• GLP-1 receptor agonists and SGLT2 inhibitors gained share on outcomes and cardiometabolic risk profiles.
• Pioglitazone is widely available generically, which tends to compress value growth for any fixed-dose combination that includes it.
• DPP-4 inhibitors still generate baseline sales in established cohorts but face persistent share erosion where formularies prefer newer classes.

This matters because OSENI’s value proposition depends on two levers:

1. Differentiation of a fixed-dose combination versus separate generic components.
2. Prescriber persistence in populations where DPP-4 remains clinically favored.

What does OSENI’s financial trajectory look like?

OSENI is commercially active in the United States and is referenced in the FDA’s prescribing ecosystem, but the financial trajectory has historically been constrained by:

• Generic exposure risk (pioglitazone and portions of DPP-4 class economics)
• Downward pricing pressure as formularies tighten and payers favor newer agents
• Limited incremental differentiation in fixed-dose therapy when both components are commonly available independently (often generically)

Net effect: OSENI’s sales potential tends to track overall DPP-4 franchise stability rather than participate in the strongest growth segments of diabetes (GLP-1 and SGLT2). As a result, the product’s commercial profile typically shows mature, slower-growth behavior rather than expansion.

How do payer dynamics and formulary mechanics affect OSENI?

OSENI demand is influenced by standard diabetes formulary rules:

• Step edits (initiation with metformin, then oral sequencing)
• Therapeutic interchange within oral classes
• Preferred class lists often directing new starts toward SGLT2 inhibitors and GLP-1 receptor agonists
• Quantity limits or restrictions depending on regional contracting

Where payers treat DPP-4 inhibitors as non-preferred, OSENI’s growth ceiling compresses through:

• Reduced new starts
• Substitution to preferred alternatives
• Switch-back volatility when coverage changes

What are the key market drivers supporting OSENI?

Despite competitive pressure, OSENI retains structural demand drivers:

• Oral fixed-dose convenience can improve adherence versus multi-pill regimens.
• Clinician familiarity with alogliptin-containing regimens and TZD pharmacology.
• Use in specific patient subgroups where oral therapy remains appropriate and GLP-1/SGLT2 options are constrained by contraindications, tolerability, or coverage.

What are the key headwinds for OSENI?

The primary headwinds are structural rather than episodic:

• Class-level share shift away from DPP-4 inhibitors
• Generic substitution dynamics tied to pioglitazone availability
• Payer preference for agents with stronger cardiometabolic positioning
• Limited differentiation once both components can be obtained separately

What role does product lifecycle play?

OSENI sits in a market segment where:

• Fixed-dose combinations face formula churn as genericization spreads and payers optimize net cost.
• Sales trajectories often transition from growth to stabilization and then decline or stagnation depending on payer mix and competitive landscape.

Where does OSENI fit versus other oral diabetes combinations?

In fixed-dose and oral combination space, OSENI competes with:

• Metformin combinations (dominant base due to metformin’s role and generic availability)
• DPP-4 + metformin fixed-dose products (strong because metformin is cheap and DPP-4 remains usable)
• SGLT2/DPP-4 and GLP-1-based combinations where available (more outcome-driven and increasingly preferred)

OSENI’s competitive position is therefore weaker than combinations aligned with the modern “outcomes-first” payer trend.

Financial trajectory: scenario mapping by competitive intensity

Without introducing unverified figures, the trajectory can be mapped by observable market mechanisms:

Driver	If favorability increases	If favorability declines
Formulary placement	Stabilized demand, more new starts	Share erosion from preferred-class switching
Net pricing	Less discounting pressure	Higher discounts to retain accounts, margin compression
Patient mix	More patients needing oral regimens	More patients moved to GLP-1/SGLT2 pathways
Competitive substitution	Slower class substitution	Faster migration to lower-cost preferred options

Given the long-run direction of diabetes prescribing and payer preference, the baseline expectation is a mature plateau followed by gradual erosion relative to outcome-oriented categories.

What observable proof exists in OSENI’s regulatory/commercial footprint?

OSENI is an FDA-prescription product with formal prescribing information and labeling context, indicating ongoing availability in regulated US commerce and clinical use pathways. The prescribing framework defines its role in type 2 diabetes management and anchors its clinical positioning in combination therapy. (See FDA label.) [1]

Key Takeaways

• OSENI’s market position depends on fixed-dose convenience and DPP-4 + TZD niche persistence in a landscape increasingly dominated by GLP-1 and SGLT2.
• Its financial trajectory is constrained by generic substitution pressure for pioglitazone economics and formulary preference shifts away from DPP-4 as newer outcomes-driven agents expand.
• The product typically behaves like a mature, stability-first diabetes franchise rather than a growth engine, with performance most sensitive to formulary tiering and net pricing.

FAQs

1) What is OSENI used for?
OSENI is used for type 2 diabetes as a fixed-dose combination of alogliptin and pioglitazone in appropriate patients requiring combination therapy. [1]

2) Why does OSENI face structural pricing pressure?
Pioglitazone is widely available and OSENI’s incremental value is harder to defend versus separate components and newer preferred drug classes, increasing payer leverage on net price.

3) How does payer preference affect OSENI sales?
When SGLT2 inhibitors and GLP-1 receptor agonists are preferred for new starts, DPP-4-based oral combinations tend to see slower growth and share loss, especially in competitive contracting.

4) Does OSENI compete only in oral diabetes?
Primarily yes on channel/formulary placement, but it competes for patient and prescriber attention against injectable and oral outcomes-based therapies that increasingly steer treatment selection.

5) What is the main commercial lever for OSENI?
Formulary access and tier placement, since OSENI’s value proposition is adherence convenience rather than a strong outcomes differentiator.

---

References

[1] U.S. Food and Drug Administration. OSENI (alogliptin and pioglitazone) prescribing information. FDA. https://www.accessdata.fda.gov/